Sutro Biopharma

Historical price data

Sutro Biopharma is advancing a differentiated ADC platform and pipeline with the goal of redefining cancer therapy. Its core XpressCF® technology enables the cell-free synthesis and site-specific conjugation of proteins, allowing for the creation of homogeneous ADCs with optimized properties. The company's strategy combines internal development of lead assets, like luveltamab tazevibulin, with strategic platform partnerships to validate its technology. Despite a challenging market valuation, Sutro's clinical progress and platform capabilities position it as a unique player in the competitive ADC landscape.

The XpressCF® platform is a proprietary, integrated cell-free protein synthesis system that enables site-specific incorporation of non-natural amino acids for the precise creation of homogeneous antibody-drug conjugates (ADCs) and other protein therapeutics.